This meant that even if a Part D plan wanted to cover a weight loss drug, it could not legally do so
Development of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Obesity Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide and semaglutide, were initially developed for the treatment of type 2 diabetes but were found to be effective not only in reducing blood glucose levels but body weight as well [18,19,20]
"Do not buy weight-loss drugs from unverified websites, influencers, or ads
Even though both Mounjaro and Zepbound contain the same active ingredient (tirzepatide), Zepbound is more likely to be covered by Aetna for weight management because it is an FDA-approved indication
Enhancing Patient Outcomes with GLP-1 Agonists Improving patient outcomes with the use of GLP-1 receptor agonists extends beyond merely selecting an appropriate medication